Immutep Ltd
eftilagimod alfa (efti)
non-small cell lung cancer (1L NSCLC)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews eftilagimod alfa (efti) for non-small cell lung cancer (1L NSCLC) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 12h ago
“TACTI-004 (KEYNOTE-F91) Phase III trial evaluating efti in first line non-small cell lung cancer (1L NSCLC)”